Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Pignata, Sandro ^a   De Placido, Sabino ^b   Biamonte, Rosalbino ^c   Scambia, Giovanni ^d   Di Vagno, Giovanni ^e   Colucci, Giuseppe ^f   Febbraro, Antonio ^g   Marinaccio, Marco ^e   Lombardi, Alessandra Vernaglia ^h   Manzione, Luigi ⁱ   Cartenì, Giacomo ^j   Nardi, Mario ^k   Danese, Saverio ^l   Valerio, Maria Rosaria ^m   de Matteis, Andrea ⁿ   Massidda, Bruno ^o   Gasparini, Giampietro ^p   Di Maio, Massimo ^q   Pisano, Carmela ^a   Perrone, Francesco ^q  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Mariano Santo Hospital   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h Clinica Malzoni   (Italy)

ⁱ SAN CARLO HOSPITAL   (Italy)

^j CARDARELLI HOSPITAL   (Italy)

^k BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^l S ANNA HOSPITAL   (Italy)

^m UNIVERSITY OF PALERMO   (Italy)

ⁿ National Cancer Institute   (Italy)

^o UNIVERSITY OF CAGLIARI   (Italy)

^p SAN FILIPPO NERI HOSPITAL   (Italy)

^q NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; OVARY CANCER; PREVALENCE; PROBABILITY; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; CHEMICALLY INDUCED DISORDER; FEMALE; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOPOTECAN;

EID: 30644462055     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-5     Document Type: Article

References (18)

1. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-1329.
2. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC: Exploratory phase III study of cisplatin and paclitaxel versus carboplatin and paclitaxel in advanced ovarian cancer. J Clin Oncol 2000, 18:3084-3092.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:2460-2465.
4. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C; ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099-2106.
5. National Cancer Institute - Cancer Therapy Evaluation Program. Common Toxicity Criteria. Version 2.0 April 30, 1999 [http://ctep.info.nih.gov]
6. Markman M, Kennedy A, Webster K, Kulp B, Peter D, Belinson J: Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 2001, 127:55-61.
7. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96: 1682-1691.
8. Kuroi K, Shimozuma K: Neurotoxicity of taxanes: sympthoms and quality of life assessment. Breast Cancer 2004, 11:92-99.
9. Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A: Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 2004, 22:2461-2468.
10. Greimel E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L, Holzner B, Kuljanic K, Lebrec J, D'haese S; EORTC Quality of Life Group and the Quality of Life Unit: An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003, 39:1402-1408.
11. De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Carteni G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004, 22:2635-2642.
12. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 1958, 53:457-81.
13. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D; Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003, 21: 2460-2465.
14. Cavalletti G, Bogliun G, Marzorati L, Zincone A, Colombo N, Tredici G: Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 1995, 76:916-917.
15. Verstappen CC, Postma TJ, Geldof AA, Heimans J: Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anticancer Res 2004, 24:2337-2341.
16. Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, Chew L, Lim SH, Wee J, Lee KM, Foo KF, Ang P, Ang PT: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003, 21:1767-1774.
17. Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau F, Scambia G; Multicenter Italian Trials in Ovarian Cancer investigators: Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003, 14:1086-1093.
18. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G: Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-Carnitine. Clin Cancer Res 2003, 9:5756-5767.